Cytocast Screener, Cytocast Optimizer, and Cytocast Nominator

Cytocast is a techbio startup that uses AI-powered predictive modeling and Digital Twin technology to evaluate the side effects of chemical compounds in pharmaceutical research. The CYTOCAST DIGITAL TWIN Platform™ creates realistic, dynamic models of human cells capable of simulating billions of molecular interactions per second, enabling research teams to forecast adverse events and make smarter, evidence-based decisions at every stage of drug discovery and preclinical development.

Cytocast offers three distinct products — Cytocast Screener™, Cytocast Optimizer™, and Cytocast Nominator™ — each designed to address a specific phase of the drug development pipeline, from early compound screening through to final lead nomination. Together, they help pharmaceutical teams prioritize the most promising drug candidates, reduce wasted resources, and de-risk the path to clinical trials.

Cytocast Screener™ — Early Compound Triage

• Application: Designed for use in the dry lab phase, before new chemical syntheses are undertaken.
• Advantage: Efficiently clusters hundreds to thousands of compounds while flagging potential side-effect liabilities, enabling research teams to eliminate weaker candidates earlier in the process.
• Benefits: Facilitates rapid "fail fast" decisions, significantly reducing the time and costs associated with pursuing suboptimal compounds. Cytocast Screener™ accelerates early detection by selecting the most promising candidates, providing interactive reports detailing potential side effects, and helping teams focus resources on compounds with the highest probability of success.

Cytocast Optimizer™ — Preclinical Candidate Refinement

• Application: Used during early and late-phase preclinical studies.
• Advantage: Refines candidate selection following in vitro and in vivo testing by enriching understanding with adverse event analyses and comparative analyses. Delivers actionable insights on prioritized candidates, including detailed mechanistic explanations that may underlie predicted side effects. Optionally incorporates secondary pharmacology data to support confident down-selection decisions.
• Benefits: Supports evidence-based decision-making in the preclinical phase, helping teams eliminate unworthy candidates before costly late-stage development. Research teams can more confidently focus on the final few candidates, reducing the time and resources required to arrive at a final selection and defend their project.

Cytocast Nominator™ — Lead and Backup Candidate Selection

• Application: Used at the stage of selecting "lead" and "backup" drug candidates for clinical development.
• Advantage: Provides sophisticated, fully interactive reports that quantify adverse-event risk profiles with unparalleled depth for final candidates, optimizing clinical trial decision-making.
• Benefits: Incorporates state-of-the-art, in-depth consideration of the probabilities of adverse effects in clinical trials, making a major contribution to preventing disastrous project outcomes. Features optional drug–drug interaction predictions and safety profile comparisons against competing therapies to de-risk lead nomination. Delivers comprehensive reports and detailed outcome analyses of final candidates, enabling pharmaceutical companies to optimize clinical trial design and execution with greater confidence.

Underlying Technology

• Cytocast uses computer simulations to determine the most effective treatments for patients while minimizing potential side effects.
• The platform models proteins, binding sites, regulatory pathways, and multiple tissue types to generate predictive safety insights.
• The Digital Twin approach enables virtual drug testing, simulating billions of molecular interactions per second to replicate realistic human cell behavior.
• Predictive outputs cover a broad range of side effects and adverse events, providing mechanistic explanations to support scientific understanding and regulatory discussions.

Cytocast's three-product suite is designed to integrate seamlessly across the drug discovery and preclinical workflow, providing pharmaceutical research teams with earlier, more interpretable safety insights at each decision-making milestone. The platform was formally launched to market with the announcement of all three products, reflecting Cytocast's mission to deliver safer drugs, faster.